Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience
Due to the multisystemic nature of the disease and its heterogeneous clinical presentation, close collaboration between neurologists and cardiologists is highly recommended, ideally within a multidisciplinary amyloidosis team, to provide holistic care in hATTRv patients.
Authors
- Stéphanie Delstanche (ORCID: https://orcid.org/0000-0003-4481-579X)
- Pierre Troisfontaines (ORCID: https://orcid.org/0000-0003-3528-3496)
- Kristl G. Claeys (ORCID: https://orcid.org/0000-0001-9937-443X)
- Gauthier Remiche (ORCID: https://orcid.org/0000-0002-4882-3570)
- Vinciane Van Parys (ORCID: https://orcid.org/0000-0003-4741-123X)
- Jan De Bleecker (ORCID: https://orcid.org/0000-0002-1328-1812)
- Antoine Bondue (ORCID: https://orcid.org/0000-0002-4103-515X)
Institutions
- Allen Institute for Brain Science (US)
- Université Libre de Bruxelles (BE)
- Erasmus Hospital (BE)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
- Centre hospitalier régional de la Citadelle (BE)
- AZ Sint-Lucas (BE)
- UCLouvain (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Acta Clinica Belgica
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1080/17843286.2025.2464971
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Alnylam Pharmaceuticals